James D. Chalmers

37.7k total citations · 6 hit papers
483 papers, 14.4k citations indexed

About

James D. Chalmers is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Emergency Medical Services. According to data from OpenAlex, James D. Chalmers has authored 483 papers receiving a total of 14.4k indexed citations (citations by other indexed papers that have themselves been cited), including 352 papers in Pulmonary and Respiratory Medicine, 164 papers in Epidemiology and 80 papers in Emergency Medical Services. Recurrent topics in James D. Chalmers's work include Cystic Fibrosis Research Advances (260 papers), Neonatal Respiratory Health Research (151 papers) and Tracheal and airway disorders (96 papers). James D. Chalmers is often cited by papers focused on Cystic Fibrosis Research Advances (260 papers), Neonatal Respiratory Health Research (151 papers) and Tracheal and airway disorders (96 papers). James D. Chalmers collaborates with scholars based in United Kingdom, Italy and United States. James D. Chalmers's co-authors include Adam T. Hill, Aran Singanayagam, Stefano Aliberti, Ahsan R. Akram, Simon Finch, Melissa J. McDonnell, Pieter Goeminne, Thomas C. Fardon, Francesco Blasi and Holly R. Keir and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

James D. Chalmers

442 papers receiving 14.1k citations

Hit Papers

The Bronchiectasis Severi... 2014 2026 2018 2022 2014 2021 2018 2017 2020 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Bronchiectasis Severity Index. An International Derivation and Validation Study
    2014 665 citations James D. Chalmers, Pieter Goeminne et al. American Journal of Respiratory and Critical Care Medicine profile →
  2. Pneumonia
    2021 411 citations Catia Cillóniz, James D. Chalmers et al. profile →
  3. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity
    2018 269 citations Patrick A. Flume, James D. Chalmers et al. profile →
  4. Neutrophil Elastase Activity Is Associated with Exacerbations and Lung Function Decline in Bronchiectasis
    2017 247 citations James D. Chalmers, Guillermo Suárez-Cuartín et al. American Journal of Respiratory and Critical Care Medicine profile →
  5. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
    2020 207 citations James D. Chalmers, Charles Haworth et al. profile →
  6. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
    2025 26 citations James D. Chalmers, Pierre‐Régis Burgel et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
James D. Chalmers 8.9k 5.2k 1.4k 1.3k 1.3k 483 14.4k
Francesco Blasi 6.3k 0.7× 7.2k 1.4× 2.4k 1.7× 1.1k 0.9× 2.1k 1.6× 590 16.1k
Stefano Aliberti 5.1k 0.6× 3.5k 0.7× 718 0.5× 624 0.5× 1.6k 1.2× 350 9.6k
Linda S. Elting 6.4k 0.7× 2.2k 0.4× 1.1k 0.8× 916 0.7× 1.0k 0.8× 195 15.6k
Adam T. Hill 4.8k 0.5× 3.4k 0.6× 704 0.5× 305 0.2× 564 0.4× 149 8.0k
Christopher H. Goss 7.7k 0.9× 2.2k 0.4× 737 0.5× 1.0k 0.8× 423 0.3× 236 10.4k
Alison Morris 5.8k 0.6× 6.4k 1.2× 674 0.5× 2.0k 1.5× 3.4k 2.6× 197 13.1k
Sanjay Sethi 7.5k 0.8× 3.9k 0.7× 2.9k 2.0× 2.0k 1.5× 541 0.4× 223 11.7k
Suzanne Havstad 1.9k 0.2× 5.2k 1.0× 1.6k 1.1× 1.2k 0.9× 348 0.3× 156 11.9k
Adrienne G. Randolph 4.9k 0.5× 5.5k 1.0× 513 0.4× 995 0.8× 2.0k 1.5× 161 16.8k
Santiago Ewig 4.4k 0.5× 10.6k 2.0× 1.1k 0.8× 542 0.4× 1.6k 1.3× 263 15.9k

Countries citing papers authored by James D. Chalmers

Since Specialization
Citations

This map shows the geographic impact of James D. Chalmers's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James D. Chalmers with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James D. Chalmers more than expected).

Fields of papers citing papers by James D. Chalmers

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James D. Chalmers. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James D. Chalmers. The network helps show where James D. Chalmers may publish in the future.

Co-authorship network of co-authors of James D. Chalmers

This figure shows the co-authorship network connecting the top 25 collaborators of James D. Chalmers. A scholar is included among the top collaborators of James D. Chalmers based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James D. Chalmers. James D. Chalmers is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chalmers, James D., Michal Shteinberg, Sanjay H. Chotirmall, et al.. (2025). Study Design of a Phase III Study (AIRTIVITY®) of the Novel Cathepsin C (Dipeptidyl Peptidase 1) Inhibitor BI 1291583 in People With Bronchiectasis. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A1964–A1964. 1 indexed citations
2.
Haworth, Charles, Pamela J. McShane, David Mauger, et al.. (2025). Efficacy of Brensocatib in Patients With Non-Cystic Fibrosis Bronchiectasis With vs Without Maintenance Use of Macrolides: An Analysis of the ASPEN Trial. American Journal of Respiratory and Critical Care Medicine. 211(Supplement_1). A3495–A3495.
3.
Richardson, Hollian, Clare Clarke, Abirami Veluchamy, et al.. (2025). The effect of different inhaled corticosteroid and long-acting bronchodilator combinations on the airway microbiome in patients with severe COPD: a randomised trial (MUSIC). European Respiratory Journal. 66(4). 2500287–2500287.
4.
Metersky, Mark L., Pierre‐Régis Burgel, Charles L. Daley, et al.. (2024). ANNUALIZED EXACERBATION RATE IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS BY PRESPECIFIED SUBGROUPS IN THE PH3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED ASPEN TRIAL. CHEST Journal. 166(4). A6554–A6556. 2 indexed citations
5.
Cagney, Kathleen A., M. J. Shepherd, Elizabeth Grimsey, et al.. (2024). Global genomic diversity of Pseudomonas aeruginosa in bronchiectasis. Journal of Infection. 89(5). 106275–106275. 3 indexed citations
6.
7.
Mall, Marcus, Jane C. Davies, Scott H. Donaldson, et al.. (2023). P094 A Phase II study to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of BI 1291583 in patients with cystic fibrosis bronchiectasis (the Clairafly™ study). Journal of Cystic Fibrosis. 22. S92–S92. 5 indexed citations
8.
Chalmers, James D., Ralph Kettritz, & Brice Korkmaz. (2023). Dipeptidyl peptidase 1 inhibition as a potential therapeutic approach in neutrophil-mediated inflammatory disease. Frontiers in Immunology. 14. 1239151–1239151. 27 indexed citations
9.
Goyal, Vikas, Sanjeewa Kularatna, Anne B. Chang, et al.. (2023). The Economic Burden of Bronchiectasis. CHEST Journal. 164(6). 1396–1421. 23 indexed citations
10.
Chotirmall, Sanjay H., Debby Bogaert, James D. Chalmers, et al.. (2022). Therapeutic Targeting of the Respiratory Microbiome. American Journal of Respiratory and Critical Care Medicine. 206(5). 535–544. 41 indexed citations
11.
Gallacher, Peter J., Robert W. Hunter, Moneeza K. Siddiqui, et al.. (2022). Cardiovascular outcomes in patients with chronic kidney disease and COVID-19: a multi-regional data-linkage study. European Respiratory Journal. 60(5). 2103168–2103168. 8 indexed citations
12.
Elborn, J.S., Francesco Blasi, Charles Haworth, et al.. (2022). Bronchiectasis and inhaled tobramycin: A literature review. Respiratory Medicine. 192. 106728–106728. 21 indexed citations
13.
14.
Gomes, Margarida C., Manman Guo, Grant Buchanan, et al.. (2020). A membrane-depolarizing toxin substrate of the Staphylococcus aureus type VII secretion system mediates intraspecies competition. Proceedings of the National Academy of Sciences. 117(34). 20836–20847. 56 indexed citations
15.
Davies, Katherine A., Cheree Fitzgibbon, Samuel N. Young, et al.. (2020). Distinct pseudokinase domain conformations underlie divergent activation mechanisms among vertebrate MLKL orthologues. Nature Communications. 11(1). 3060–3060. 45 indexed citations
16.
Chalmers, James D., et al.. (2019). Assessment of Phenotype Microarray plates for rapid and high-throughput analysis of collateral sensitivity networks. PLoS ONE. 14(12). e0219879–e0219879. 6 indexed citations
17.
Restrepo, Marcos I., Luis Felipe Reyes, James D. Chalmers, et al.. (2018). Burden and risk factors for Pseudomonas aeruginosa community-acquired pneumonia: a multinational point prevalence study of hospitalised patients. Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona). 12 indexed citations
18.
Rodrigo‐Troyano, Ana, Guillermo Suárez-Cuartín, Diego Castillo, et al.. (2016). Pseudomonas aeruginosa resistance patterns and clinical outcomes in hospitalized exacerbations of COPD. Respirology. 21(7). 1235–1242. 38 indexed citations
19.
Singanayagam, Aran, James D. Chalmers, & Adam T. Hill. (2009). Admission hypoglycaemia is associated with adverse outcome in community-acquired pneumonia. European Respiratory Journal. 34(4). 932–939. 16 indexed citations
20.
Chalmers, James D.. (2008). Lieser and misconceptions. ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Francesco Blasi Breakdown of academic impact, for papers by Stefano Aliberti Breakdown of academic impact, for papers by Linda S. Elting Breakdown of academic impact, for papers by Adam T. Hill Breakdown of academic impact, for papers by Christopher H. Goss Breakdown of academic impact, for papers by Alison Morris Breakdown of academic impact, for papers by Sanjay Sethi Breakdown of academic impact, for papers by Suzanne Havstad Breakdown of academic impact, for papers by Adrienne G. Randolph Breakdown of academic impact, for papers by Santiago Ewig
Rankless by CCL
2026